The offer is the latest in a series of deals by Concentra, an entity controlled by Tang Capital Partners, to buy struggling ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

January kicked off the year with a flurry of notable leadership transitions across the pharmaceutical and biotechnology sectors. Here is a detailed look at the latest hires and departures.

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number of changes at the big pharmas, which may have slipped under your radar ...

Jazz Pharmaceuticals (JAZZ) stock gains as its lung cancer therapy Zepzelca, in combination with Roche's Tecentriq, receives ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality. According to the deal, ...

US health chief says Sen. Cassidy promised pick on vaccine panel Healthcare & Pharmaceuticalscategory · 8:09 PM UTC · Updated ago U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy ...

BioNTech announces CureVac acquisition for $1.25 billion in stock to strengthen cancer therapy pipeline and mRNA technology ...